



## News Release

### **Suven to Present at Alzheimer's Association International Conference (AAIC)**

**HYDERABAD, INDIA (17 July 2015)** – Several exciting new results and data presentations from Suven's portfolio of investigational neuroscience new chemical entities (NCEs) are being presented at **Alzheimer's Association International Conference (AAIC)** being held in Washington DC, USA during July 18-23, 2015

**AAIC is the world's largest conference of its kind, where thousands of researchers from more than 70 countries will gather to reveal the latest study results, theories and discoveries bringing the world closer to breakthroughs in dementia science.**

Alzheimer's disease is one of the scourges of modern day health care which is the largest and fastest growing unmet medical need and Suven is in the forefront of developing a drug for the treatment of this debilitating disease. Alzheimer's is not just a memory loss as everyone thinks but Alzheimer's kills. **Alzheimer's is the only cause of death among the top 10 in America without a way to prevent, cure or even slow its progression.**

**Suven has excellent portfolio of new molecules through four mechanisms of action using 5-HT<sub>6</sub>, 5-HT<sub>4</sub>, H<sub>3</sub> and Neuronal Nicotinic acetylcholine receptors for the symptomatic treatment of cognitive impairment in Alzheimer's disease but also possibly useful in reducing the disease progression.** Suven scientists are presenting pre-clinical and clinical data on these molecule and other NCEs on memory related disorders and major depressive disorder.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. **The Company has eleven (11) internally-discovered therapeutic drug candidates currently** in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to Phase 2 ready **developmental candidate SUVN-502 for and Phase1 candidate SUVN-G3031 for Alzheimer's disease and Schizophrenia.**

For more information please visit our Web site at <http://www.suven.com>

#### Risk Statement:

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*